322 Chemoradiotherapy for unresectable endometrial cancer: case series

• Published in: International journal of gynecological cancer Vol. 33; no. Suppl 3; pp. A149 - A150
• Main Authors: Ching-López, Rosario, Vargas, Pillar, Carbonell, María, Lara, Ana María
• Format: Journal Article
• Language: English
• Published: Oxford BMJ Publishing Group LTD 01.09.2023
• Subjects: Cancer therapies; Chemotherapy; Endometrial cancer; Radiation therapy; Toxicity
• ISSN: 1048-891X; 1525-1438
• DOI: 10.1136/ijgc-2023-ESGO.307

Introduction/BackgroundEndometrial cancer is a common malignancy affecting women worldwide, and in some cases, surgical resection may be challenging due to its advanced stage. Historically, these cases were managed palliatively but, even if there is still a paucity of literature about this topic, chemoradiotherapy has emerged as an effective treatment option lately. The aim of this case series is to provide clinicians and researchers with a comprehensive understanding of the role of this approach in the management of unresectable endometrial cancer.MethodologyWe retrospectively reviewed 5 patients diagnosed with FIGO stage IIIB-VA endometrial cancer in our institution, treated between 2020 and 2022. They completed treatment with Intensity-Modulated Radiation Therapy (IMRT) (dose 48.6 Gy in 1.8 Gy fractions given on 5 days per week) given with concurrent chemotherapy (consisting of two cycles of cisplatin 50 mg/m2 during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2). They were then reevaluated with MRI and stratified to receive definite high dose rate (HDR) brachytherapy or surgery. Progression-free survival (PFS), local control (LC), overall survival (OS), and grade ≥3 toxicities were reported.ResultsMedian age was 51 (range: 42–78) with median follow-up being 11 months (range: 5–24). Four patients were downstaged and received surgery followed by intracavitary HDR brachytherapy, while 1 of them did not show any radiological response and received intrauterine HDR brachytherapy. The actuarial 1-year LC, PFS and OS were 90%, 80%, and 100%. There were no acute grade ≥3 toxicities. There were 2 late grade ≥3 toxicities due to urinary toxicity and gastrointestinal side effects.ConclusionThe combination of radiotherapy and chemotherapy is a safe treatment option for women with locally extensive unresectable endometrial cancer, with favorable local control and limited toxicity in 5 patients treated with this approach. Further studies are needed to optimize this treatment modality.DisclosuresThe authors have no conflicts of interest to declare. All co-authors have seen and agree with the contents of the manuscript and there is no financial interest to report. We certify that the submission is original work and is not under review at any other publication.